APA (7th ed.) Citation

Y, C., Y, Z., H, S., W, Y., H, X., Y, L., & Z, D. (2026). Personalized neoantigen DC vaccine combined with camrelizumab following definitive therapy in locally advanced unresectable esophageal squamous cell carcinoma (CHANT-241): Protocol for a randomized controlled trial. Frontiers in immunology, 16, 1658670. https://doi.org/10.3389/fimmu.2025.1658670

Chicago Style (17th ed.) Citation

Y, Chen, Zheng Y, Shi H, Yang W, Xu H, Li Y, and Ding Z. "Personalized Neoantigen DC Vaccine Combined with Camrelizumab Following Definitive Therapy in Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (CHANT-241): Protocol for a Randomized Controlled Trial." Frontiers in Immunology 16 (2026): 1658670. https://doi.org/10.3389/fimmu.2025.1658670.

MLA (9th ed.) Citation

Y, Chen, et al. "Personalized Neoantigen DC Vaccine Combined with Camrelizumab Following Definitive Therapy in Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (CHANT-241): Protocol for a Randomized Controlled Trial." Frontiers in Immunology, vol. 16, 2026, p. 1658670, https://doi.org/10.3389/fimmu.2025.1658670.